Literature DB >> 26711770

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Wesley D Oliver1, Emily L Heil1, Jeffrey P Gonzales2, Shailly Mehrotra3, Kathryn Robinett4, Paul Saleeb4, David P Nicolau5.   

Abstract

Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa in a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284.38 μg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26711770      PMCID: PMC4775955          DOI: 10.1128/AAC.02608-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacodynamics of cefepime in patients with Gram-negative infections.

Authors:  Vincent H Tam; Peggy S McKinnon; Ronda L Akins; Michael J Rybak; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

2.  Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Authors:  Benjamin Miller; Ellie Hershberger; David Benziger; Mymy Trinh; Ian Friedland
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.

Authors:  Emily L Heil; Ashleigh V Lowery; Kerri A Thom; David P Nicolau
Journal:  Pharmacotherapy       Date:  2014-12-29       Impact factor: 4.705

Review 4.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

5.  Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Don-Kelena Awissi; Annie Beauchamp; Elisabeth Hébert; Viviane Lavigne; Danya Lucia Munoz; Geneviève Lebrun; Michel Savoie; Mylène Fagnan; Julie Amyot; Nicolas Tétreault; Robert Robitaille; France Varin; Christian Lavallée; Vincent Pichette; Martine Leblanc
Journal:  Pharmacotherapy       Date:  2015-06       Impact factor: 4.705

6.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

Authors:  Myra Wooley; Benjamin Miller; Gopal Krishna; Ellie Hershberger; Gurudatt Chandorkar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

8.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

  8 in total
  13 in total

Review 1.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

2.  Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies.

Authors:  Nieves Carbonell; Gerardo Aguilar; Rafael Ferriols; Rotzel Huerta; José Ferreres; Marisa Calabuig; Mar Juan; Carlos Ezquer; Javier Colomina; M Luisa Blasco
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

3.  Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration.

Authors:  Gerardo Aguilar; Rafael Ferriols; Sara Martínez-Castro; Carlos Ezquer; Ernesto Pastor; José A Carbonell; Manuel Alós; David Navarro
Journal:  Crit Care       Date:  2019-04-26       Impact factor: 9.097

4.  Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury.

Authors:  Laura Butragueño-Laiseca; Iñaki F Troconiz; Santiago Grau; Nuria Campillo; Xandra García; Belén Padilla; Sarah N Fernández; María José Santiago
Journal:  Antibiotics (Basel)       Date:  2020-12-10

Review 5.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423

6.  Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.

Authors:  J Monterrubio-Villar; S Rodríguez-Garrido; J D Jiménez-Delgado
Journal:  Rev Esp Quimioter       Date:  2018-07-09       Impact factor: 1.553

Review 7.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

Review 8.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

9.  A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.

Authors:  Fekade B Sime; Melissa Lassig-Smith; Therese Starr; Janine Stuart; Saurabh Pandey; Suzanne L Parker; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

10.  Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam.

Authors:  Olga Rodríguez-Núñez; Leonor Periañez-Parraga; Antonio Oliver; Jose M Munita; Anna Boté; Oriol Gasch; Xavier Nuvials; Aurélien Dinh; Robert Shaw; Jose M Lomas; Vicente Torres; Juanjo Castón; Rafael Araos; Lilian M Abbo; Robert Rakita; Federico Pérez; Samuel L Aitken; Cesar A Arias; M Luisa Martín-Pena; Asun Colomar; M Belén Núñez; Josep Mensa; José Antonio Martínez; Alex Soriano
Journal:  Open Forum Infect Dis       Date:  2019-09-28       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.